Opinion|Videos|November 19, 2024
Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd
This episode reviews the response rates reported in the HERTHENA-Lung01 trial among patients with advanced NSCLC exhibiting various resistance mechanisms, evaluates the clinical significance of responses to HER3-DXd based on HER3 expression scores, discusses the relevance of the reported overall DOR, median PFS, and OS, and examines the CNS ORR among patients with baseline brain metastases in relation to the ORRs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please share your impressions of the response rates reported in HERTHENA-Lung01 among patients with EGFR-dependent, EGFR-independent, or both EGFR-dependent and -independent resistance mechanisms in advanced or metastatic NSCLC.
- How clinically meaningful are the responses to HER3-DXd across a range of pretreatment, HER3 expression scores in patients with heavily pretreated ,advanced, or metastatic NSCLC?
- Please comment on the overall 6.4-month DOR, median PFS of 5.5 months, and OS of 11.9 months reported in HERTHENA-Lung01. Are these data meaningful to you?
- Please share your thoughts on the CNS ORR of 33.3% among the 10 study subjects with baseline brain metastases who attained CR or PR vis-à-vis the confirmed ORR of 29.8%.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5